Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Newron Pharmaceuticals
Newron Pharmaceuticals
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Neopac showcases latest tube, dispensing and cap innovations at Pharmapack Paris
Highlights include company’s reduced material LowPro caps and world’s smallest child resistant tube
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
You need to be a subscriber to read this article.
Click here
to find out more.
Parenteral preparations: formulation challenges
Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are...
Lonza’s capsule delivers acid-sensitive ingredients to the intestine
The capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Safinamide to be made available in Asia for Parkinson's
Meiji Seika and Eisai enter into a collaboration for the development and commercialisation of safinamide in Parkinson’s disease for Japan and Asia
FDA approves Xadago for Parkinson’s patients
Xadago (safinamide) is first NCE approved in the USA for PD patients with motor fluctuations in a decade
Pharmaceutical
Newron starts operations in New Jersey, US
Two senior executives join the company and will be located in Morristown, New Jersey
Regulatory
Parkinson’s disease – safinamide
The effectiveness of dopamine agonist drugs to treat Parkinson\'s disease decreases over time as more and more dopamine-producing cells die
Research & Development
Newron receives €2.5m grant from Wellcome Trust
To fund clinical trial for amyotrophic lateral sclerosis (ALS)
Finance
Newron to acquire NeuroNova for €15.4m
Gains two Phase II compounds for progressive neurogenerative diseases
Research & Development
Newron and Zambon enter into a new €5m agreement for safinamide
Zambon will make a total investment in Newron of €20m
Subscribe now